Is a complete XERS research report available?

No complete published report is available for Xeris Biopharma Holdings, Inc. (XERS) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Xeris Biopharma Holdings, Inc. (XERS)

NASDAQ: XERS · USD

$10.6

+0.19 (+1.8%)· Recorded snapshot

Market cap	1.9B
Revenue (ttm)	335.4M
Net income (ttm)	-17.2M
EPS (ttm)	-$0.10
Shares out	182.3M
P/E (forward)	70.3x
Volume	1,199,422
Beta	0.84

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 335.4M
Net income (ttm): -17.2M
EPS (ttm): -$0.10
P/E (forward): 70.3x
Market cap: 1.9B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

Metric	Value
Amount currency	USD
CIK code	0001867096
Company name	Xeris Biopharma Holdings, Inc.
Country	United States
Country code	US
CUSIP number	98422E103
Earnings date	2026-11-05
Earnings time	bmo
Employees	435
Employees change	41
Employees growth	10.41%
Enterprise value	$2.1B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2005
In index	RUSSELL2000
Industry	Drug Manufacturers - Specialty & Generic
IPO date	2018-06-21
Is primary listing	Yes
Is SPAC	No
ISIN number	US98422E1038
Last 10-K release date	2026-03-02
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1.9B
Market cap category	Small-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$10.64
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	XERS
U.S. state	Illinois
Website	https://www.xerispharma.com

Metric

Value

Amount currency

USD

CIK code

0001867096

Company name

Xeris Biopharma Holdings, Inc.

Country

United States

Country code

CUSIP number

98422E103

Earnings date

2026-11-05

Earnings time

bmo

Employees

435

Employees change

Employees growth

10.41%

Enterprise value

$2.1B

Exchange

NASDAQ

Financial currency

USD

Financial report date

2026-06-30

First seen

2026-05-09

Fiscal year end

December

Founded

2005

In index

RUSSELL2000

Industry

Drug Manufacturers - Specialty & Generic

IPO date

2018-06-21

Is primary listing

Yes

Is SPAC

ISIN number

US98422E1038

Last 10-K release date

2026-03-02

Last earnings date

2026-08-06

Last refreshed

2026-10-28

Last stock split type

Never

Market cap

$1.9B

Market cap category

Small-Cap

Next earnings date

2026-11-05

Options

Yes

Price

$10.64

Price currency

USD

Sector

Healthcare

SIC code

2834

Stock price date

2026-10-28

Symbol

XERS

U.S. state

Illinois

Website

https://www.xerispharma.com

Metric	Value
Adjusted P/E ratio	156.01x
Earnings yield	-0.96%
EV/EBIT	58.09x
EV/EBITDA	43.59x
EV/FCF	38.19x
EV/Sales	6.34x
FCF / EV yield	2.62%
FCF yield	2.84%
Forward EV/Sales	4.91x
Forward P/E	70.27x
Forward P/S	4.53x
Industry forward P/E	13.87x
Industry P/E	173.94x
P/(FCF - SBC) ratio	71.08x
P/(OCF - SBC) ratio	68.74x
P/FCF ratio	35.17x
P/OCF ratio	34.59x
P/S ratio	5.84x
Price/EBITDA ratio	40.15x
Sector forward P/E	23.56x
Sector P/E	50.08x

Metric

Value

Adjusted P/E ratio

156.01x

Earnings yield

-0.96%

EV/EBIT

58.09x

EV/EBITDA

43.59x

EV/FCF

38.19x

EV/Sales

6.34x

FCF / EV yield

2.62%

FCF yield

2.84%

Forward EV/Sales

4.91x

Forward P/E

70.27x

Forward P/S

4.53x

Industry forward P/E

13.87x

Industry P/E

173.94x

P/(FCF - SBC) ratio

71.08x

P/(OCF - SBC) ratio

68.74x

P/FCF ratio

35.17x

P/OCF ratio

34.59x

P/S ratio

5.84x

Price/EBITDA ratio

40.15x

Sector forward P/E

23.56x

Sector P/E

50.08x

Metric	Value
EBIT margin	10.91%
EBITDA margin	14.54%
FCF margin	16.6%
Gross margin	86.58%
Operating margin	10.91%
Pretax margin	-5.12%
Profit margin	-5.12%
Profit per employee	$-39,460
Profitable years	1
Revenue per employee	$771,067
ROA	6.13%
ROA (5Y)	-10.92%
ROCE	16.46%
ROIC	8.84%
SBC / revenue	8.38%

Metric

Value

EBIT margin

10.91%

EBITDA margin

14.54%

FCF margin

16.6%

Gross margin

86.58%

Operating margin

10.91%

Pretax margin

-5.12%

Profit margin

-5.12%

Profit per employee

$-39,460

Profitable years

Revenue per employee

$771,067

ROA

6.13%

ROA (5Y)

-10.92%

ROCE

16.46%

ROIC

8.84%

SBC / revenue

8.38%

Metric	Value
EPS growth years	0
FCF growth (QoQ)	-15.62%
Gross profit growth	43.52%
Gross profit growth (Q)	33.45%
Gross profit growth 3Y	38.35%
Gross profit growth 5Y	67.12%
Net income growth years	4
OCF growth (Q)	4,440.11%
OCF growth (QoQ)	-16.28%
Operating income growth (Q)	15.42%
Revenue growth	36.33%
Revenue growth (Q)	28.74%
Revenue growth (QoQ)	10.79%
Revenue growth 3Y	35.75%
Revenue growth 5Y	58.32%
Revenue growth quarters	27
Revenue growth years	9

Metric

Value

EPS growth years

FCF growth (QoQ)

-15.62%

Gross profit growth

43.52%

Gross profit growth (Q)

33.45%

Gross profit growth 3Y

38.35%

Gross profit growth 5Y

67.12%

Net income growth years

OCF growth (Q)

4,440.11%

OCF growth (QoQ)

-16.28%

Operating income growth (Q)

15.42%

Revenue growth

36.33%

Revenue growth (Q)

28.74%

Revenue growth (QoQ)

10.79%

Revenue growth 3Y

35.75%

Revenue growth 5Y

58.32%

Revenue growth quarters

Revenue growth years

Metric	Value
Capital expenditures	$-938,000
Depreciation and amortization	$12.2M
EBIT	$36.6M
EBITDA	$48.8M
EPS	$-0.10
FCF per share	$0.31
Financing cash flow	$6.7M
Free cash flow	$55.7M
Free cash flow minus SBC	$27.5M
Gross profit	$290.4M
Investing cash flow	$-938,000
Net cash flow	$62.4M
Net income	$-17.2M
Operating cash flow minus SBC	$28.5M
Operating income	$36.6M
Revenue	$335.4M
Stock-based compensation	$28.1M

Metric

Value

Capital expenditures

$-938,000

Depreciation and amortization

$12.2M

EBIT

$36.6M

EBITDA

$48.8M

EPS

$-0.10

FCF per share

$0.31

Financing cash flow

$6.7M

Free cash flow

$55.7M

Free cash flow minus SBC

$27.5M

Gross profit

$290.4M

Investing cash flow

$-938,000

Net cash flow

$62.4M

Net income

$-17.2M

Operating cash flow minus SBC

$28.5M

Operating income

$36.6M

Revenue

$335.4M

Stock-based compensation

$28.1M

Metric	Value
Altman Z-Score	0.6
Book value per share	$-0.06
Debt / EBITDA	5.1
Debt / FCF	5.2
Goodwill	$22.9M
Interest coverage	1.3
Long-term assets	$137.1M
Long-term liabilities	$232.1M
Net cash (debt)	$-167.7M
Net cash / market cap	-8.56%
Net debt / EBITDA	3.44
Net debt / FCF	3.01
Piotroski F-Score	6
Property, plant and equipment	$26.6M
Shareholders' equity	$-9.7M
Tangible book value	$-115.3M
Tangible book value per share	$-0.66
Total assets	$411.9M
Total cash	$121.7M
Total debt	$289.4M
Total liabilities	$421.6M
WACC	8.71%

Metric

Value

Altman Z-Score

0.6

Book value per share

$-0.06

Debt / EBITDA

5.1

Debt / FCF

5.2

Goodwill

$22.9M

Interest coverage

1.3

Long-term assets

$137.1M

Long-term liabilities

$232.1M

Net cash (debt)

$-167.7M

Net cash / market cap

-8.56%

Net debt / EBITDA

3.44

Net debt / FCF

3.01

Piotroski F-Score

Property, plant and equipment

$26.6M

Shareholders' equity

$-9.7M

Tangible book value

$-115.3M

Tangible book value per share

$-0.66

Total assets

$411.9M

Total cash

$121.7M

Total debt

$289.4M

Total liabilities

$421.6M

WACC

8.71%

Metric	Value
Asset turnover	0.9
Current assets	$274.8M
Current liabilities	$189.6M
Current ratio	1.45
Inventory turnover	0.61
Net working capital	$33.5M
Quick ratio	0.95
Working capital	$85.2M
Working capital turnover	3.82

Metric

Value

Asset turnover

0.9

Current assets

$274.8M

Current liabilities

$189.6M

Current ratio

1.45

Inventory turnover

0.61

Net working capital

$33.5M

Quick ratio

0.95

Working capital

$85.2M

Working capital turnover

3.82

Metric	Value
Buyback yield / dilution	-10.29%
Dividend yield	0%
Shareholder yield	-10.29%

Metric

Value

Buyback yield / dilution

-10.29%

Dividend yield

Shareholder yield

-10.29%

Metric	Value
150-day SMA	$7.76
1D price change	1.82%
1M price change	17.31%
1M total return	17.31%
1W price change	-4.09%
1W total return	-4.09%
1Y price change	14.66%
1Y return CAGR	14.67%
1Y total return	14.66%
20-day SMA	$10.27
200-day SMA	$7.47
3M price change	30.02%
3M total return	30.02%
3Y price change	563.04%
3Y return CAGR	87.84%
3Y total return	563.04%
50-day SMA	$9.23
50-day SMA vs 200-day SMA	50over200
52-week high	$11.42
52-week high date	2026-10-19
52-week low	$5.25
52-week low date	2026-03-25
5Y price change	483.33%
5Y return CAGR	42.3%
5Y total return	483.33%
6M price change	74.43%
6M total return	74.43%
All-time high	$11.42
All-time high date	2026-10-19
All-time low	$0.97
All-time low date	2023-01-05
Average true range (ATR)	$0.50
Average volume	2.3M
Beta (1Y)	1.43
Beta (2Y)	1.09
Beta (5Y)	0.84
Change from 52-week high	-6.79%
Change from 52-week low	102.67%
Change from all-time high	-6.48%
Change from all-time low	1,000.4%
Change from open	1.82%
Day's gap	0%
Dollar volume	$12.8M
High price	$10.75
Low price	$10.45
Monthly RSI	72.29
Open price	$10.45
Position in 52-week range	63.33%
Premarket change	-0.38%
Premarket close	$10.45
Premarket price	$10.41
Premarket volume	5.6K
Previous close	$10.45
Price vs 150-day SMA	37.53%
Price vs 20-day SMA	3.95%
Price vs 200-day SMA	42.92%
Price vs 50-day SMA	15.68%
Relative volume	0.51
RSI	59.85
Sharpe ratio	0.46
Sharpe ratio (3Y)	1.26
Sharpe ratio (5Y)	0.77
Sortino ratio	0.73
Sortino ratio (3Y)	2.11
Sortino ratio (5Y)	1.33
Volume	1.2M
Weekly RSI	70.02
YTD price change	35.99%
YTD total return	35.99%

Metric

Value

150-day SMA

$7.76

1D price change

1.82%

1M price change

17.31%

1M total return

17.31%

1W price change

-4.09%

1W total return

-4.09%

1Y price change

14.66%

1Y return CAGR

14.67%

1Y total return

14.66%

20-day SMA

$10.27

200-day SMA

$7.47

3M price change

30.02%

3M total return

30.02%

3Y price change

563.04%

3Y return CAGR

87.84%

3Y total return

563.04%

50-day SMA

$9.23

50-day SMA vs 200-day SMA

50over200

52-week high

$11.42

52-week high date

2026-10-19

52-week low

$5.25

52-week low date

2026-03-25

5Y price change

483.33%

5Y return CAGR

42.3%

5Y total return

483.33%

6M price change

74.43%

6M total return

74.43%

All-time high

$11.42

All-time high date

2026-10-19

All-time low

$0.97

All-time low date

2023-01-05

Average true range (ATR)

$0.50

Average volume

2.3M

Beta (1Y)

1.43

Beta (2Y)

1.09

Beta (5Y)

0.84

Change from 52-week high

-6.79%

Change from 52-week low

102.67%

Change from all-time high

-6.48%

Change from all-time low

1,000.4%

Change from open

1.82%

Day's gap

Dollar volume

$12.8M

High price

$10.75

Low price

$10.45

Monthly RSI

72.29

Open price

$10.45

Position in 52-week range

63.33%

Premarket change

-0.38%

Premarket close

$10.45

Premarket price

$10.41

Premarket volume

5.6K

Previous close

$10.45

Price vs 150-day SMA

37.53%

Price vs 20-day SMA

3.95%

Price vs 200-day SMA

42.92%

Price vs 50-day SMA

15.68%

Relative volume

0.51

RSI

59.85

Sharpe ratio

0.46

Sharpe ratio (3Y)

1.26

Sharpe ratio (5Y)

0.77

Sortino ratio

0.73

Sortino ratio (3Y)

2.11

Sortino ratio (5Y)

1.33

Volume

1.2M

Weekly RSI

70.02

YTD price change

35.99%

YTD total return

35.99%

Metric	Value
Float	176.1M
Float percentage	96.57%
Shares change (QoQ)	-2.71%
Shares change (YoY)	10.29%
Shares held by insiders	3.43%
Shares held by institutions	61.54%
Shares outstanding	182.3M
Short % of float	4.09%
Short % of shares	3.95%
Short ratio	2.5 days

Metric

Value

Float

176.1M

Float percentage

96.57%

Shares change (QoQ)

-2.71%

Shares change (YoY)

10.29%

Shares held by insiders

3.43%

Shares held by institutions

61.54%

Shares outstanding

182.3M

Short % of float

4.09%

Short % of shares

3.95%

Short ratio

2.5 days

Xeris Biopharma Holdings, Inc. (XERS)

Price

Financial snapshot

Fair-value bridge

Latest news · XERS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All XERS indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on XERS

Frequently asked questions